COVID-19 Coinfection With Mucormycosis in a Diabetic Patient

Roopa, Ramya; Thanthoni, Malarkodi; Warrier, Aravind S

doi:10.7759/cureus.15820

Cited by 10 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More severe orbital complications could occur in COVID-19 patients with coexisting systemic comorbidities and the use of immunosuppressive agents such as steroids. Various cases of development of rhino-orbital mucormycosis were reported in COVID-19 patients with pre-existing diabetes mellitus (DM) and subjected to parenteral broad-spectrum antibiotics and steroids 39–46 . In these patients, ophthalmic examination revealed extensive edema of the periorbital region with soft tissue necrosis along the eyelids, proptosis, conjunctival edema, exposure keratopathy, decreased visual acuity, and restricted extraocular movement 47 .…”

Section: Resultsmentioning

confidence: 99%

“…Various cases of development of rhino-orbital mucormycosis were reported in COVID-19 patients with preexisting diabetes mellitus (DM) and subjected to parenteral broadspectrum antibiotics and steroids. [39][40][41][42][43][44][45][46] In these patients, ophthalmic examination revealed extensive edema of the periorbital region with soft tissue necrosis along the eyelids, proptosis, conjunctival edema, exposure keratopathy, decreased visual acuity, and restricted extraocular movement. 47 Fatal cases resulting from rhino-orbital cerebral mucormycosis in COVID-19 have also been documented.…”

Section: Orbitmentioning

confidence: 93%

See 1 more Smart Citation

COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations

Lin

Zheng

et al. 2021

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) came under the attention of the international medical community when China first notified the World Health Organization of a pneumonia outbreak of then-unknown etiology in Wuhan in December 2019. Since then, COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has appalled the world by spreading at a pandemic speed. Although ophthalmologists do not directly engage in the clinical care of COVID-19 patients, the ophthalmology community has become aware of the close ties between its practice and the pandemic. Not only are ophthalmologists at heightened risk of SARS-CoV-2 exposure due to their physical proximity with patients in routine ophthalmic examinations, but SARS-CoV-2 possesses ocular tropism resulting in ocular complications beyond the respiratory tract after viral exposure. Furthermore, patients could potentially suffer from adverse ocular effects in the therapeutic process. This review summarized the latest literature to cover the ophthalmic manifestations, effects of treatments, and vaccinations on the eye to aid the frontline clinicians in providing effective ophthalmic care to COVID-19 patients as the pandemic continues to evolve.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Orbitmentioning

confidence: 93%

COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations

Lin

Zheng

et al. 2021

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…[4][5][6] The SARS-CoV-2 infectivity is morphologically different from earlier identified coronavirus that caused pneumonia. On 11 March 2020, COVID-19 was declared by WHO as a pandemic and in April 2021, COVID-19 infectivity was confirmed among 135 million individuals with 2.92 million fatalities across the globe, 7 with a case fatality rate (CFR) of about 5.4 % and an infection fatality rate of 0.9 %. Among low and middle-income states, Pakistan was the first country affected by the epidemic and the reported coronavirus cases were 398,024 with 8025 mortalities (CFR 2.51%) by the year 2020.…”

Section: Introductionmentioning

confidence: 99%

Is mucormycosis an addition to the pandemic spectrum: An observational study

Ilyas,

Niaz,

Khan

et al. 2024

BioMedica

View full text Add to dashboard Cite

Abstract: Introduction and Objective: A concerning increase in occurrences of mucormycosis, known as COVID-19 Associated Mucormycosis (CAM), has been reported worldwide in people who are coping with COVID-19. The exact relationship between mucormycosis and COVID-19 is yet unknown, despite this apparent correlation. In order to ascertain the degree to which mucormycosis and coronavirus illness are associated, this study aims to clarify the nature of this association. Method: This study, which was an observational one, examined 35 individuals who had been diagnosed with mucormycosis. At Lahore General Hospital in Lahore, the ENT Department conducted this study to thoroughly evaluate the relationship between mucormycosis and coronavirus disease, patient demographics, such as age, gender, COVID-19 status, and co-morbidities, were carefully documented.   Results: The majority of the patients (54.3%) were male, and the average age of those enrolled in the study was 49.40 ± 13.511 years. Of the patients, 25.7% had confirmed COVID-19 positive. Notably, diabetes mellitus was the predominant co-morbidity in a significant proportion of patients (74.3%), followed by DM/CKD (11.4%), DM/CLD (8.6%), and DM/HTN (5.7%). The findings of the statistical analysis showed that co-morbidities and COVID-19 were significantly correlated (P<0.05) in mucormycosis patients, whereas age and gender were not significantly correlate (P>0.05). Conclusion: In summary, this study suggests that mucormycosis could be an additional aspect of the pandemic's spectrum. The data from our study supports this claim, since a significant percentage (25.7%) of patients with mucormycosis also had a COVID-19 diagnosis concomitantly. The significance of more research and increased awareness about the co-occurrence of COVID-19 and mucormycosis in clinical settings is highlighted by this study.

show abstract

“…With the inception of the COVID-19 pandemic in India since March 2020 and its rapid spread and upsurge during the second wave in 2021, the panic and havoc amongst Indians and rest of the world has risen [1,2]. The second wave of the COVID-19 pandemic showed its heavy impact, along with a complication in the form of the occurrence of COVID-19associated mucormycosis in many patients across the world.…”

Section: Introductionmentioning

confidence: 99%

“…However, its occurrence in India was huge compared to other parts of the world [1]. This presentation left the medical fraternity with a big challenge regarding the identification of its confirmatory cause, prevention, and management [1,2]. As most of the states in India, especially Maharashtra, have recorded a growing trend of confirmed mucormycosis cases in post-COVID-19 patients, the disease has been declared as an epidemic [3].…”

Section: Introductionmentioning

confidence: 99%

Oral Tissue Involvement and Probable Factors in Post-COVID-19 Mucormycosis Patients: A Cross-Sectional Study

et al. 2022

View full text Add to dashboard Cite

The primary goal of this study was to assess the prevalence of oral involvement and, secondarily, the likely variables in patients with confirmed COVID-19 accompanied by mucormycosis infection. The study design was a cross-sectional descriptive sort that was performed at a tertiary centre. The non-probability convenience sampling approach was used to determine the sample size. Between May 2021 and July 2021, all patients who presented to our tertiary care centre with suspected mucormycosis were considered for the investigation. The research only included individuals with proven mucormycosis after COVID-19. The features of the patients, the frequency of intraoral signs/symptoms, and the possible variables were all noted. Of the 333 COVID-19-infected patients, 47 (14%) were diagnosed with confirmed mucormycosis. The mean (SD) age of the patients was 59.7 (11.9) years. Of the 47 patients with confirmed mucormycosis, 34% showed sudden tooth mobility, 34% expressed toothache, 8.5% reported palatal eschar, 34% presented with jaw pain, 8.5% had tongue discoloration, and 17% had temporomandibular pain. About 53% of the patients were known cases of type 2 diabetes mellitus, 89% of patients had a history of hospitalization due to COVID-19 infection, 89.3% underwent oxygen support therapy, and 89.3% were administered intravenous steroids during hospitalization due to COVID-19 infection. About 14% of the suspected cases attending the mucormycosis out-patient department (OPD) had been confirmed with definite mucormycosis. Oral involvement was seen in 45% of cases of CAM (COVID-associated mucormycosis). The most frequent oral symptoms presented in CAM were sudden tooth mobility and toothache. Diabetes and steroids were the likely contributing factors associated with CAM.

show abstract

COVID-19 Coinfection With Mucormycosis in a Diabetic Patient

Cited by 10 publications

References 21 publications

COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations

COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations

Is mucormycosis an addition to the pandemic spectrum: An observational study

Oral Tissue Involvement and Probable Factors in Post-COVID-19 Mucormycosis Patients: A Cross-Sectional Study

Contact Info

Product

Resources

About